Clear Program Physician Webpage
Information specifically for physicians to help your patient understand PAD. Learn More »
Chronic Limb-Threatening Ischemia (CLTI) is a severe form of peripheral artery disease (PAD) that can lead to amputation and increased mortality/cardiovascular events.1 Now, Abbott's Esprit™ BTK System offers a breakthrough innovation for you and your patients as the first-and-only FDA-approved drug-eluting resorbable scaffold for CLTI. The only BTK device that does it all:
In the LIFE-BTK Trial, Esprit™ BTK demonstrated superior efficacy compared to PTA at the 1-year mark, with a 30.8% improvement in primary patency and limb salvage, establishing a new standard of care for infrapopliteal arterial disease in patients with chronic limb-threatening ischemia (CLTI).6
The 2-year results from the LIFE-BTK Trial, presented at VIVA 2024, showed a sustained improvement with Esprit™ BTK compared to PTA, with a 28.7% improvement in primary patency and limb salvage, and a comparable safety profile through two years.7
Esprit™ BTK significantly reduced the rate of clinically-driven target lesion revascularization (CD-TLR), with 48% fewer patients requiring repeat interventions compared to PTA.7
Watch how the Esprit™ BTK System does it all for CLTI: addressing vessel recoil and dissection,2 combined with a drug to inhibit neointimal hyperplasia,4 and then fully resorbs over time,5 preserving future treatment options.
Physicians share their experience with the Esprit™ BTK System and the advantages it delivers in treating their patients and improving outcomes.
New Technology Add-on Payment (NTAP)
Effective October 1, 2025, EspritTM BTK Everolimus Eluting Resorbable Scaffold inpatient procedures may be eligible for an incremental payment from Medicare.1 This incremental reimbursement is called New Technology Add-on Payment (NTAP).
Centers for Medicare and Medicaid Services (CMS) has determined that the EspritTM BTK System NTAP maximum is $6,922.50.1
For more details regarding NTAP, including examples of how NTAP is calculated and frequently asked questions, please refer to the reimbursement resouces available on Vascular Coding and Coverage Resources | Abbott
The proper code utilization will trigger a calculation of the NTAP payment by your Medicare Administrator Contractor’s claims processing system. Please refer to the table below for the appropriate ICD-10-PCS codes that describe the use of the EspritTM BTK System.
CMS has issued the following New Technology ICD-10-PCS (procedure) codes for the implantation of everolimus-eluting resorbable scaffold system in below-the-knee arteries, effective October 1, 2024.
ICD-10 PCS CODE | DESCRIPTION2 |
---|---|
X27P3TA | Dilation of right anterior tibial artery with intraluminal device, everolimus-eluting resorbable scaffold(s), percutaneous approach, new technology group 10 |
X27Q3TA | Dilation of left anterior tibial artery with intraluminal device, everolimus-eluting resorbable scaffold(s), percutaneous approach, new technology group 10 |
X27R3TA | Dilation of right posterior tibial artery with intraluminal device, everolimus-eluting resorbable scaffold(s), percutaneous approach, new technology group 10 |
X27S3TA | Dilation of left posterior tibial artery with intraluminal device, everolimus-eluting resorbable scaffold(s), percutaneous approach, new technology group 10 |
X27T3TA | Dilation of right peroneal artery with intraluminal device, everolimus-eluting resorbable scaffold(s), percutaneous approach, new technology group 10 |
X27U3TA | Dilation of left peroneal artery with intraluminal device, everolimus-eluting resorbable scaffold(s), percutaneous approach, new technology group 10 |
References:
See the Vascular Health Economics and Reimbursement website for additional resources
For additional questions, please contact Abbott’s Reimbursement Hotline at 855-569-6430
(Monday - Friday, 8 am –5 pm Central Time) or AbbottEconomics@abbott.com
The material and the information contained herein is for general information purposes only and is not intended, and does not constitute, legal, reimbursement, business, clinical or other advice. Furthermore, it is not intended to and does not constitute a representation or guarantee of reimbursement, payment, or charge, or that reimbursement or other payment will be received. It is not intended to increase or maximize payment by any payer. Abbott makes no express or implied warranty or guaranteed that the list of codes and narratives in this document is complete or error-free. Similarly, nothing in this document should be viewed as instructions for selecting any particular code, and Abbott does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding and obtaining payment/reimbursement remains with the customer. This includes the responsibility for accuracy and veracity of all coding and claims submitted to third-party payers. In addition, the customer should note that laws, regulations, and coverage policies are complex and are updated frequently, and therfore, the customer should check with its local carriers or intermediaries often and should consult with legal counsel or a financial, coding, or reimbursement specialist for any questions related to coding, billing, reimbursement, or any related issues. This material reproduces information for reference purposes only. It is not provided or authorized for marketing use.
Diameter | 18 | 28 | 38 | Sheath (F) | Maximum Post-Dilation Diameter | Nominal/RBP Inflation Pressure |
---|---|---|---|---|---|---|
2.5 mm | 1212250-18 | 1212250-28 | 1212250-38 | 5F (0.070"/1.8 mm) | 3.0 mm | 9/16 ATM |
3.0 mm | 1212300-18 | 1212300-28 | 1212300-38 | 5F (0.070"/1.8 mm) | 3.5 mm | 9/16 ATM |
3.5 mm | 1212350-18 | 1212350-28 | 1212350-38 | 5F (0.070"/1.8 mm) | 4.0 mm | 9/16 ATM |
3.75 mm | 1212375-18 | 1212375-28 | 1212375-38 | 5F (0.070"/1.8 mm) | 4.25 mm | 9/16 ATM |
Diameter | 18 | 28 | 38 | Sheath (F)1 | Maximum Post-Dilation Diameter1 | Nominal/RBP Inflation Pressure1 |
---|---|---|---|---|---|---|
2.5 mm | 1203250-18 | 1203250-28 | 1203250-38 | 5F (0.070"/1.8 mm) | 3.0 mm | 9/16 ATM |
3.0 mm | 1203300-18 | 1203300-28 | 1203300-38 | 5F (0.070"/1.8 mm) | 3.5 mm | 9/16 ATM |
3.5 mm | 1203350-18 | 1203350-28 | 1203350-38 | 5F (0.070"/1.8 mm) | 4.0 mm | 9/16 ATM |
3.75 mm | 1203375-18 | 1203375-28 | 1203375-38 | 5F (0.070"/1.8 mm) | 4.25 mm | 9/16 ATM |
Esprit™ BTK Everolimus Eluting Resorbable Scaffold Instructions for Use (IFU). Refer to IFU for additional information.
Beyond the treatment, make sure your referring physicians are fully aware of PAD and CLTI and how they can help with early diagnosis and timely treatment. For information specifically for the physician, visit our Clear Program webpage. Access a full range of helpful tools and insights. And for your patients, refer them to the PAD-info.com link to support the work you do, so they can learn about PAD symptoms and access an educational brochure.
MAT-2403385 v6.0
The Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is indicated for improving luminal diameter in infrapopliteal lesions in patients with chronic limb-threatening ischemia (CLTI) and total scaffolding length up to 170 mm with a reference vessel diameter of ≥ 2.5 mm and ≤ 4.00 mm.
The Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is contraindicated for use in:
Potential adverse events include, but are not limited to:
Allergic reaction or hypersensitivity to contrast agent, anesthesia, scaffold materials (poly[L-lactide] [PLLA], poly[D, L-lactide] [PDLLA], platinum, or everolimus), and drug reactions to anticoagulation or antiplatelet drugs
The risks described below include the anticipated adverse events referenced in the contraindications, warnings, and precautions sections of the everolimus labels / SmPCs and / or observed at incidences ≥ 10% in clinical trials with oral everolimus for different indications. Refer to the drug SmPCs and labels for more detailed information and less frequent adverse events.
There may be other potential adverse events that are unforeseen at this time.
MAT-2403616 v1.0
Stay Connected